A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome

PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: George, Charles F. P., Feldman, Neil, Zheng, Yanping, Steininger, Teresa L., Grzeschik, Susanna M., Lai, Chinglin, Inhaber, Neil
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2010
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3098358/
https://ncbi.nlm.nih.gov/pubmed/20082240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11325-009-0320-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars